[Featured Stock] Jinwon Life Sciences Surges on COVID Vaccine Clinical Trial Recruitment
[Asia Economy Reporter Ji Yeon-jin] Jinwon Life Sciences is showing a sharp rise following the news of recruiting subjects for the Phase 2a clinical trial of the novel coronavirus (COVID-19) vaccine.
As of 10:15 AM on the 6th, Jinwon Life Sciences is trading on the KOSPI market at 41,000 KRW, up 20.06% (6,700 KRW) compared to the previous day.
On this day, Jinwon Life Sciences announced that it has signed an agreement with the National Clinical Trial Support Foundation to receive support for recruiting subjects for the Phase 2a clinical trial of the COVID-19 vaccine 'GLS-5310'.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
The company explained that in the Phase 2a trial involving 300 subjects, an additional elderly group aged 85 and above will be included, and the GLS-5310 1.2mg dose will be administered twice at 8-week intervals. Additionally, subjects participating in the placebo control group will be able to receive GLS-5310 or the national vaccine 4 weeks after the last dose.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
